For example, high IFIT3 expression predicted better response to IFN-α therapy in hepatocellular carcinoma patients59, and its knockdown attenuated chemoresistance of pancreatic cancer cells to gemcitabine and paclitaxel therapy60. This evidence concerns the gene IFIT3 and familial pancreatic carcinoma.